CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 124 enrolled
Drug / intervention
Pegcetacoplan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05067127
NCT05067127Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Apellis Pharmaceuticals, Inc.·interventional·Posted Oct 5, 2021·Updated Jan 29, 2026

In Brief

A Phase 3 clinical trial evaluating Pegcetacoplan and Placebo for C3G and 11 related conditions. Completed, enrolled 124 participants across 125 sites in 19 countries.

Detailed Summary

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Israel, Italy, Japan, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedOct 5, 2021
Enrollment StartNov 12, 2021
Primary CompletionJun 26, 2024
Study CompletionJan 14, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.7 years ago

Interventions

Pegcetacoplandrug

Complement (C3) Inhibitor

Placeboother

Sterile solution of equal volume to active arm